Is AN 33501 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use AN 33501? Is AN 33501 safe for nursing mother and child? Does AN 33501 extracts into breast milk? Does AN 33501 has any long term or short term side effects on infants? Can AN 33501 influence milk supply or can AN 33501 decrease milk supply in lactating mothers?
AN 33501 lactation summary
- DrLact safety Score for AN 33501 is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of AN 33501 may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that AN 33501 may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using AN 33501 .
- Usage of AN 33501 is in contradiction to breastfeeding hence if it is must to use AN 33501 and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About AN 33501 usage in lactation
Drug is cleared from the body in 10 elimination half-lives. Resuming breastfeeding is likely safe after 24 hours of pumping-and-dumping.
Answer by DrLact: About AN 33501 usage in lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence. Although minimal data are available to determine an appropriate period to withhold breastfeeding, the drug's terminal half-live of 2.5 hours suggests that withholding breastfeeding for at least 24 hours may be sufficient. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[3]
AN 33501 Side Effects in Breastfeeding
AN 33501 in a dosage of 4 mg/day for 5 weeks was taken for myeloid leukemia by one woman while breastfeeding. Weekly monitoring found no adverse effects on her infant's leukocyte count or hemoglobin.[3]
Alternate Drugs
Cyclophosphamide(Dangerous)
Busulfan(Dangerous)
Letrozole(Dangerous)
Exemestane(Dangerous)
Vincristine(Dangerous)
Dasatinib(Unsafe)
Tamoxifen(Dangerous)
Nilotinib(Unsafe)
Mitoxantrone(Dangerous)
Dactinomycin(Dangerous)
Ipilimumab(Unsafe)
Mercaptopurine(Safe)
Cetuximab(Unsafe)
Carboplatin(Dangerous)
Hydroxyurea(Low Risk)
Paclitaxel(Dangerous)
Etoposide(Dangerous)
Fluorouracil(Dangerous)
Doxorubicin(Dangerous)
Gemcitabine(Dangerous)
Alemtuzumab(Low Risk)
Nivolumab(Unsafe)
Rituximab(Low Risk)
Vinblastine(Dangerous)
Bevacizumab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Cyclophosphamide(Dangerous)
Pazopanib(Unsafe)
Vinorelbine(Dangerous)
Cisplatin(Unsafe)
Trastuzumab(Unsafe)
Dacarbazine(Dangerous)
Imatinib(Unsafe)
Busulfan(Dangerous)
Thioguanine(Dangerous)
Azelaic Acid(Safe)
Erlotinib(Unsafe)
Cladribine(Dangerous)